400 related articles for article (PubMed ID: 21263219)
1. Combined modality therapy with TRAIL or agonistic death receptor antibodies.
Amm HM; Oliver PG; Lee CH; Li Y; Buchsbaum DJ
Cancer Biol Ther; 2011 Mar; 11(5):431-49. PubMed ID: 21263219
[TBL] [Abstract][Full Text] [Related]
2. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
[TBL] [Abstract][Full Text] [Related]
3. TRAIL receptor signaling and therapeutics.
Abdulghani J; El-Deiry WS
Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
[TBL] [Abstract][Full Text] [Related]
4. TRAIL-based therapeutic approaches for the treatment of pediatric malignancies.
Gasparini C; Vecchi Brumatti L; Monasta L; Zauli G
Curr Med Chem; 2013; 20(17):2254-71. PubMed ID: 23458616
[TBL] [Abstract][Full Text] [Related]
5. The long and winding road to cancer treatment: the TRAIL system.
Palacios C; Yerbes R; Sanchez-Perez T; Martin-Perez R; Cano-Gonzalez A; Lopez-Rivas A
Curr Pharm Des; 2014; 20(17):2819-33. PubMed ID: 23944369
[TBL] [Abstract][Full Text] [Related]
6. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
Cretney E; Takeda K; Smyth MJ
Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.
Abdulghani J; Allen JE; Dicker DT; Liu YY; Goldenberg D; Smith CD; Humphreys R; El-Deiry WS
PLoS One; 2013; 8(9):e75414. PubMed ID: 24086526
[TBL] [Abstract][Full Text] [Related]
8. Targeting death-receptors in radiation therapy.
Niemöller O; Belka C
Results Probl Cell Differ; 2009; 49():219-39. PubMed ID: 19582410
[TBL] [Abstract][Full Text] [Related]
9. TRAIL: a sword for killing tumors.
Wang S
Curr Med Chem; 2010; 17(29):3309-17. PubMed ID: 20712573
[TBL] [Abstract][Full Text] [Related]
10. Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels.
Beyrath J; Chekkat N; Smulski CR; Lombardo CM; Lechner MC; Seguin C; Decossas M; Spanedda MV; Frisch B; Guichard G; Fournel S
Oncotarget; 2016 Oct; 7(40):64942-64956. PubMed ID: 27409341
[TBL] [Abstract][Full Text] [Related]
11. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.
Bremer E; de Bruyn M; Samplonius DF; Bijma T; ten Cate B; de Leij LF; Helfrich W
J Mol Med (Berl); 2008 Aug; 86(8):909-24. PubMed ID: 18504532
[TBL] [Abstract][Full Text] [Related]
13. Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy.
Singh D; Tewari M; Singh S; Narayan G
Future Oncol; 2021 Feb; 17(5):581-596. PubMed ID: 33401962
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic targeting of CD95 and the TRAIL death receptors.
Gerspach J; Pfizenmaier K; Wajant H
Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):294-310. PubMed ID: 21762072
[TBL] [Abstract][Full Text] [Related]
15. The TRAIL apoptotic pathway in cancer onset, progression and therapy.
Johnstone RW; Frew AJ; Smyth MJ
Nat Rev Cancer; 2008 Oct; 8(10):782-98. PubMed ID: 18813321
[TBL] [Abstract][Full Text] [Related]
16. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.
Dai X; Zhang J; Arfuso F; Chinnathambi A; Zayed ME; Alharbi SA; Kumar AP; Ahn KS; Sethi G
Exp Biol Med (Maywood); 2015 Jun; 240(6):760-73. PubMed ID: 25854879
[TBL] [Abstract][Full Text] [Related]
17. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
[TBL] [Abstract][Full Text] [Related]
18. Developing TRAIL/TRAIL death receptor-based cancer therapies.
Yuan X; Gajan A; Chu Q; Xiong H; Wu K; Wu GS
Cancer Metastasis Rev; 2018 Dec; 37(4):733-748. PubMed ID: 29541897
[TBL] [Abstract][Full Text] [Related]
19. From biochemical principles of apoptosis induction by TRAIL to application in tumour therapy.
Cordier SM; Papenfuss K; Walczak H
Results Probl Cell Differ; 2009; 49():115-43. PubMed ID: 19142621
[TBL] [Abstract][Full Text] [Related]
20. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
